{"id":"permitted-dmards","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DMARDs work through various mechanisms including inhibition of T-cell activation, B-cell suppression, and reduction of pro-inflammatory cytokines. By modulating immune responses, they prevent joint damage and systemic inflammation characteristic of rheumatoid arthritis and other autoimmune conditions. The class includes both conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs).","oneSentence":"DMARDs (Disease-Modifying Antirheumatic Drugs) suppress immune system activity to reduce inflammation and slow progression of autoimmune diseases.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:07.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other autoimmune inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT00443651","phase":"PHASE3","title":"A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-01","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Permitted DMARDs","genericName":"Permitted DMARDs","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DMARDs (Disease-Modifying Antirheumatic Drugs) suppress immune system activity to reduce inflammation and slow progression of autoimmune diseases. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}